Results 31 to 40 of about 3,878,916 (126)

Analysis of severe cutaneous adverse reactions (SCARs) in Taiwan drug-injury relief system: 18-year results

Journal of the Formosan Medical Association, 2022
Background/purpose: Taiwan Drug-Injury Relief System (TDRS) has been implemented since 1999. More than 60% of the approved applications were associated with severe cutaneous adverse reactions (SCARs). Studies assessing SCARs using real-world evidence are
Po-Wei Huang, Mu-Han Chiou, Mei-Yi Chien, Wen-Wen Chen, Chia-Yu Chu   +4 more
doaj   +1 more source

Successful Management and Treatment Rechallenge Following Docetaxel-Induced Serpentine Supravenous Hyperpigmentation With Bullous Features: A Case Report. [PDF]

Clin Case Rep
ABSTRACT Serpentine supravenous hyperpigmentation (SSH) is a rare dermatological complication of intravenous chemotherapy characterized by linear hyperpigmented streaks along superficial veins. Bullous SSH represents an exceptionally rare variant with only a few previously reported cases in the literature. We report the case of a 50‐year‐old woman with
Nair GR, Koutsis J, Poels D, Agar N, Warrier S, Kumar S.   +5 more
europepmc   +2 more sources

Generalized bullous fixed drug eruption imitating toxic epidermal necrolysis: a case report and literature review [PDF]

, 2017
Fixed drug eruption (FDE) is defined as sharply demarcated erythematous patches or plaques that occur secondary to systemic exposure to a causative medication.
Hsu, Sylvia, Albahrani, Yasser, Applebaum, Danielle S, Mitre, Victoria, Yasser Albahrani, Danielle S Applebaum, Sylvia Hsu, Mitre, Victoria ; Applebaum, Danielle S ; Albahrani, Yasser ; Hsu, Sylvia, Victoria Mitre   +8 more
core   +1 more source

Pheniramine maleate: an apparently safe drug causing bullous fixed drug eruption [PDF]

, 2018
Fixed drug eruption is a delayed type hypersensitivity reaction to a drug seen most frequently with antibiotics such as tetracyclines, sulfonamides, and NSAIDs such as naproxen and ibuprofen.
Gupta, Aastha, MD, Pooja Arora, Malhotra, Purnima, MD, Kabir Sardana, Purnima Malhotra, Gupta, Aastha ; MD, Pooja Arora ; Malhotra, Purnima ; MD, Kabir Sardana, Kabir Sardana MD, Aastha Gupta, Pooja Arora MD   +8 more
core   +1 more source

Real World Use of the IL‐36 Receptor Antagonist Spesolimab: A Systematic Review and Analysis

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Spesolimab, an interleukin‐36 receptor antagonist, is approved for the treatment and prevention of generalised pustular psoriasis (GPP) flares. Its use has increasingly been reported in real‐world settings for both GPP and other inflammatory dermatoses.
Sophia A. Mense, Nicole Bavaro, Aashna Farishta, Jiaqi Chen, Raj Chovatiya   +4 more
wiley   +1 more source

Updated EAACI Statement on Drug Hypersensitivity Skin Testing: Methodology and Non‐Irritative Concentrations

Allergy, EarlyView.
ABSTRACT These updated EAACI guidelines aim to standardize skin testing methodologies for both immediate and non‐immediate drug hypersensitivity reactions. For immediate reactions, the optimal testing window is 4–6 weeks post‐reaction; whereas beyond 6 months, false‐negative results increase.
Annick Barbaud, Lene Heise Garvey, Elizabeth Phillips, Michael Ardern‐Jones, Sevim Bavbek, Patrizia Bonadonna, Jean‐Christoph Caubet, Ana‐Maria Copaescu, Valentina Gueli, Jose Julio Laguna, Ricardo Madrigal‐Burgaleta, Francesca Mori, Vito Sabato, Maria J Torres, Knut Brockow   +14 more
wiley   +1 more source

Generalized bullous fixed drug eruption is distinct from Stevens-Johnson syndrome/toxic epidermal necrolysis by immunohistopathological features

, 2017
Background: Generalized bullous fixed drug eruption (GBFDE), a particular form of fixed drug eruption (FDE), is characterized by widespread blisters and erosions and can be confused with Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).
朱家瑜, Cho, Yung-Tsu;Lin, Jheng-Wei;Chen, Yi-Chun;Chang, Chia-Ying;Hsiao, Cheng-Hsiang;Chung, Wen-Hung;Chu, Chia-Yu   +1 more
core   +1 more source

Nomenclature on Immune‐Mediated Drug Reactions: An EAACI Position Paper

Allergy, EarlyView.
ABSTRACT Over the past several decades, there have been significant advances in our understanding of both immunological and pharmacological mechanisms of adverse drug reactions (ADRs). Immune‐mediated drug reactions (IMDRs) represent a small proportion of ADRs and are caused by a pathological activation of the immune system or inflammatory pathways ...
Maria J. Torres, Cristobalina Mayorga, Elizabeth J. Phillips, Adriana Ariza, Annick Barbaud, Patrizia Bonadonna, Mariana Castells, Gülfem Çelik, Knut Brockow, Lene H. Garvey, Inmaculada Doña, Jean‐Christoph Caubet, Francesca Mori, Jason Trubiano, Giorgia Marta, Antonino Romano, Ingrid Terreehorst, Asli Gelincik, Philip H. Li, Vito Sabato   +19 more
wiley   +1 more source

Management of Non‐Plaque‐Induced Gingival Conditions: A Systematic Review—Part 2: Inflammatory and Immune Conditions; Neoplasms; and Gingival Pigmentation

Journal of Clinical Periodontology, EarlyView.
ABSTRACT Aims This systematic review assesses current evidence on the management of non‐plaque (dental biofilm)‐induced gingival diseases and conditions (NPIGDs), including (i) inflammatory and immune conditions, (ii) neoplasms and (iii) gingival pigmentations.
Maria Clotilde Carra, Cecile Wasielewski, Bruno Špiljak, Maja Sabalić‐Schoener, Sebastien Jungo, Ivan Alajbeg   +5 more
wiley   +1 more source

Levofloxacin-induced bullous fixed drug eruption: A rare case report

, 2016
Drug-induced cutaneous adverse drug reactions are very much common, especially with antibiotics. Fluoroquinolones are widely used antibiotics for different types of infective conditions.
Bhalchandra N Awari, BhalchandraN Awari, SatishE Bahekar, Ranjana S Kale, Dipankar Chakraborty, Satish E Bahekar, RanjanaS Kale, Awari, Bhalchandra N., Chakraborty, Dipankar, Kale, Ranjana S., Bahekar, Satish E.   +10 more
core   +1 more source